Tag Archives: New York Times

Love Potion #9: The Hypoactive Sexual Desire Disorder Pipeline

New products in development for women distressed by a lack of sexual desire and satisfying sexual experiences are causing a stir, but not for the reasons one might expect. Do women have less of a right than men to combat sexual disorders with pills? That’s the question eight national and international women’s advocacy groups asked […]
Posted in FDA, healthcare, leadership, Market Access, Patient Communication, R&D, Regulatory, Safety, Strategy | Also tagged , , , , , , , , | 1 Comment

Elmendorf Refuses to Go Quietly Into the Night of HCR

Guest Blog by Tom Norton of NHD Smart Communications. You can reach him at tnorton@nhdcomm.com. Amidst all the gurgling of oil last week(bad! bad! bad!), a competing thunderstorm of words erupted as Doug Elmendorf, Director of CBO, had the temerity to revisit the real costs of the new HCR law. Addressing something that, for whatever […]
Posted in Guest Blog | Also tagged , , , , , , | 2 Comments

When Big Pharma Leaves Town

Image via Wikipedia Wall Street smiles when a drug company gets with the program by “restructuring” and “rightsizing”—cutting costs through headline-grabbing layoffs. But for Main Street, the story of hundreds or thousands of sales reps, say, and researchers getting kicked to the curb is quite different. The two gi-normous mergers that closed in the past […]
Posted in Strategy | Also tagged , , , , , , | 2 Comments

Tauzin to Boehner: Don’t “Bully” Me

Image via Wikipedia PhRMA chief Billy Tauzin so far shows no sign of waving the white flag in response to an accusatory missive from House Minority Leader Rep. John Boehner bludgeoning his former Republican colleague for leading the drug industry’s support of President Obama’s healthcare reform effort. Pointedly CC’d to pharma CEOs – Tauzin’s employers—and […]
Posted in Regulatory | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta